SCHEMBL3670409

SCHEMBL3670409

CC(C)(C)OC(=O)NCCN(CC(=O)O)C(=O)Cn1ccc(NC(=O)OCc2ccccc2)nc1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.47
ABL1 P00519 2/20 0.46
RIN1 Q13671 2/20 0.46
MAPT P10636 3/20 0.43
CKS1B P61024 1/20 0.40
SKP1 P63208 1/20 0.40
SKP2 Q13309 1/20 0.40
SYK P43405 1/20 0.39
IDO1 P14902 1/20 0.36
MAP3K5 Q99683 1/20 0.35
AKT1 P31749 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HTT P42858 1/20 0.35
SIGMAR1 Q99720 2/20 0.35
POLB P06746 1/20 0.34
MAPK1 P28482 1/20 0.34
ITGB3 P05106 1/20 0.34
ITGAV P06756 1/20 0.34
LMNA P02545 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3731633 0.88 MAPT (0.45) RAB9AABL1RIN1MAPTCKS1B
SCHEMBL7717128 0.84 ABL1 (0.40) RAB9AABL1RIN1MAPTCKS1B
SCHEMBL14308496 0.83 KMT2A (0.41) RAB9AABL1RIN1MAPTCKS1B
SCHEMBL15234703 0.83 CKS1B (0.42) MAPTCKS1BSKP1SKP2AKT1
SCHEMBL6046930 0.82 MAPT (0.42) RAB9AMAPTCKS1BSKP1SKP2
SCHEMBL7900010 0.82 RAB9A (0.46) RAB9AABL1RIN1MAPTSYK
SCHEMBL8645940 0.81 MAPT (0.43) RAB9AABL1RIN1MAPTCKS1B
SCHEMBL8581017 0.81 RAB9A (0.57) RAB9AABL1RIN1MAPTSYK
SCHEMBL7900006 0.81 RAB9A (0.47) RAB9AABL1RIN1MAPTSYK
SCHEMBL5202116 0.80 SYK (0.40) RAB9AABL1RIN1MAPTCKS1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130231480-A1 SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF GENEARREST LTD (IL) 2013-09-05 US disclosed
US-20130231480-A1 SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF GENEARREST LTD (IL) 2013-09-05 US disclosed
US-20130231480-A1 SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF GENEARREST LTD (IL) 2013-09-05 US disclosed
US-20100284959-A1 SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF GENE ARREST LTD. (IL) 2010-11-11 US disclosed
US-20040009899-A1 Reducing the level of an RNA or polypeptide expressed by a mutant allele of a gene that causes a dominant disorder in a mammal by administering a polyamide nucleic acid oligomer that is heterozygous for such a mutant allele MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2004-01-15 US disclosed
US-6548651-B1 Conjugating cationic peptides to peptide nucleic acids; microbiocides PANTHECO A/S (DK) 2003-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100284959-A1 SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF POLRMT, POLM, SNRPE RAB9A 4581/4885ABL1 3074/4885RIN1 4832/4885
US-20130231480-A1 SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF POLM, POLRMT, DDB1 RAB9A 4515/4885ABL1 3090/4885RIN1 4789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.